Maravai LifeSciences Holdings Q2 2025 Earnings Preview
Earnings Announcement: Maravai LifeSciences Holdings (MRVI) will release its Q2 earnings results on August 11th, with an expected EPS of -$0.07 and revenue of $47.37M, reflecting significant year-over-year declines.
Performance History: Over the past two years, MRVI has met EPS estimates 25% of the time and revenue estimates 38% of the time, with recent revisions showing more downward adjustments than upward for both EPS and revenue.
Trade with 70% Backtested Accuracy
Analyst Views on MRVI
About MRVI
About the author
Maravai to Announce Q4 and Full Year 2025 Financial Results
- Earnings Announcement Schedule: Maravai LifeSciences plans to release its Q4 and full year 2025 financial and operational results after market close on February 25, 2026, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: The company will host a conference call on the same day at 2:00 PM PT/5:00 PM ET, allowing investors to dial in at 1-800-343-4136 or 1-203-518-9843, enhancing engagement with stakeholders.
- Webcast Availability: The conference call will be available via live or archived webcast on the
Maravai to Announce Q4 and Full Year 2025 Results
- Earnings Announcement Schedule: Maravai LifeSciences plans to release its Q4 and full year 2025 financial and operational results after market close on February 25, 2026, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: The company will host a conference call on the same day at 2:00 PM PT/5:00 PM ET, allowing investors to dial in at 1-800-343-4136 or 1-203-518-9843 to access critical information promptly.
- Webcast Availability: The conference call will also be available via live or archived webcast on the
Aptamer Licenses Optimer for Hot-Start PCR to Alphazyme, Securing Global Rights
- Licensing Agreement: Aptamer Group has entered into a licensing agreement with Alphazyme, a Maravai LifeSciences company, granting the latter a non-exclusive license to use an enzyme-modulating Optimer in hot-start PCR and next-generation sequencing applications, marking a strategic collaboration in the biotech sector.
- Global Rights Granted: The agreement provides Alphazyme with worldwide rights, including royalty payments on product sales and milestone payments, which are expected to generate a continuous revenue stream for Aptamer.
- Manufacturing Collaboration: Aptamer will manufacture the Optimer for Alphazyme, ensuring product quality control while enhancing Aptamer's manufacturing capabilities and competitive position in the biopharmaceutical industry.
- Positive Stock Reaction: Following the announcement of the agreement, Aptamer's shares rose by 4% to GBp 0.8378 on the London Stock Exchange, reflecting market optimism regarding the prospects of this collaboration.
Insider Buying Update for Wednesday, October 12: AVTR, MRVI
Avantor Insider Purchase: Sanjeev K. Mehra, Director of Avantor, bought 350,000 shares at $11.09 each, totaling $3.88 million, marking his first purchase in a year. Avantor's stock rose approximately 6.3% on Wednesday.
Maravai LifeSciences Insider Purchase: Gregory T. Lucier, Director of Maravai LifeSciences, purchased 100,000 shares at $3.69 each for a total of $368,544, with the stock up about 3.9% on Wednesday. Lucier's investment is currently showing a gain of 7.2% based on the day's trading high.
Post-Market Surge: Stoke Therapeutics, Alpha Tau Medical, and Compass Pathways Top Biotech Gainers
Biotech Stock Movements: Biotech stocks experienced significant fluctuations in after-hours trading, with several companies rebounding after losses during regular trading hours, driven by clinical data, FDA designations, and financing news.
Stoke Therapeutics Surge: Stoke Therapeutics saw its stock rise to $33.95 (+11.42%) after presenting positive data on zorevunersen for Dravet syndrome in collaboration with Biogen at a recent conference.
Alpha Tau Medical Gains: Alpha Tau Medical's shares surged by 25.26% to $5.30 after announcing the treatment of its first patient in a pilot study for recurrent glioblastoma multiforme using its Alpha DaRT technology.
FDA Designation for Senti Biosciences: Senti Biosciences' stock increased to $1.60 (+3.92%) following the FDA granting RMAT designation to its investigational CAR-NK cell therapy for acute myeloid leukemia and other hematologic malignancies.
Reminder: Bragar Eagel & Squire, P.C. Ongoing Investigation for Maravai Long-Term Shareholders
Investor Alert: Bragar Eagel & Squire, P.C. is investigating potential claims against Maravai LifeSciences Holdings, Inc. (MRVI) for long-term stockholders who experienced losses between August 7, 2024, and February 24, 2025, following a class action complaint filed on March 3, 2025.
Company Issues: Maravai announced a delay in its fiscal 2024 earnings release due to an error in revenue recognition and identified a material weakness in its internal controls, leading to a significant drop in share price.
Allegations: The class action complaint alleges that Maravai's board made misleading statements and failed to disclose critical information regarding the company's financial reporting and goodwill, which misled investors about its business prospects.
Contact Information: Long-term stockholders with information or questions are encouraged to contact Bragar Eagel & Squire, P.C. directly via phone or email for further assistance regarding their legal rights.
Maravai to Announce Q4 and Full Year 2025 Financial Results
- Earnings Announcement Schedule: Maravai LifeSciences plans to release its Q4 and full year 2025 financial and operational results after market close on February 25, 2026, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: The company will host a conference call on the same day at 2:00 PM PT/5:00 PM ET, allowing investors to dial in at 1-800-343-4136 or 1-203-518-9843, enhancing engagement with stakeholders.
- Webcast Availability: The conference call will be available via live or archived webcast on the
Maravai to Announce Q4 and Full Year 2025 Results
- Earnings Announcement Schedule: Maravai LifeSciences plans to release its Q4 and full year 2025 financial and operational results after market close on February 25, 2026, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: The company will host a conference call on the same day at 2:00 PM PT/5:00 PM ET, allowing investors to dial in at 1-800-343-4136 or 1-203-518-9843 to access critical information promptly.
- Webcast Availability: The conference call will also be available via live or archived webcast on the
Aptamer Licenses Optimer for Hot-Start PCR to Alphazyme, Securing Global Rights
- Licensing Agreement: Aptamer Group has entered into a licensing agreement with Alphazyme, a Maravai LifeSciences company, granting the latter a non-exclusive license to use an enzyme-modulating Optimer in hot-start PCR and next-generation sequencing applications, marking a strategic collaboration in the biotech sector.
- Global Rights Granted: The agreement provides Alphazyme with worldwide rights, including royalty payments on product sales and milestone payments, which are expected to generate a continuous revenue stream for Aptamer.
- Manufacturing Collaboration: Aptamer will manufacture the Optimer for Alphazyme, ensuring product quality control while enhancing Aptamer's manufacturing capabilities and competitive position in the biopharmaceutical industry.
- Positive Stock Reaction: Following the announcement of the agreement, Aptamer's shares rose by 4% to GBp 0.8378 on the London Stock Exchange, reflecting market optimism regarding the prospects of this collaboration.
Insider Buying Update for Wednesday, October 12: AVTR, MRVI
Avantor Insider Purchase: Sanjeev K. Mehra, Director of Avantor, bought 350,000 shares at $11.09 each, totaling $3.88 million, marking his first purchase in a year. Avantor's stock rose approximately 6.3% on Wednesday.
Maravai LifeSciences Insider Purchase: Gregory T. Lucier, Director of Maravai LifeSciences, purchased 100,000 shares at $3.69 each for a total of $368,544, with the stock up about 3.9% on Wednesday. Lucier's investment is currently showing a gain of 7.2% based on the day's trading high.
Post-Market Surge: Stoke Therapeutics, Alpha Tau Medical, and Compass Pathways Top Biotech Gainers
Biotech Stock Movements: Biotech stocks experienced significant fluctuations in after-hours trading, with several companies rebounding after losses during regular trading hours, driven by clinical data, FDA designations, and financing news.
Stoke Therapeutics Surge: Stoke Therapeutics saw its stock rise to $33.95 (+11.42%) after presenting positive data on zorevunersen for Dravet syndrome in collaboration with Biogen at a recent conference.
Alpha Tau Medical Gains: Alpha Tau Medical's shares surged by 25.26% to $5.30 after announcing the treatment of its first patient in a pilot study for recurrent glioblastoma multiforme using its Alpha DaRT technology.
FDA Designation for Senti Biosciences: Senti Biosciences' stock increased to $1.60 (+3.92%) following the FDA granting RMAT designation to its investigational CAR-NK cell therapy for acute myeloid leukemia and other hematologic malignancies.
Reminder: Bragar Eagel & Squire, P.C. Ongoing Investigation for Maravai Long-Term Shareholders
Investor Alert: Bragar Eagel & Squire, P.C. is investigating potential claims against Maravai LifeSciences Holdings, Inc. (MRVI) for long-term stockholders who experienced losses between August 7, 2024, and February 24, 2025, following a class action complaint filed on March 3, 2025.
Company Issues: Maravai announced a delay in its fiscal 2024 earnings release due to an error in revenue recognition and identified a material weakness in its internal controls, leading to a significant drop in share price.
Allegations: The class action complaint alleges that Maravai's board made misleading statements and failed to disclose critical information regarding the company's financial reporting and goodwill, which misled investors about its business prospects.
Contact Information: Long-term stockholders with information or questions are encouraged to contact Bragar Eagel & Squire, P.C. directly via phone or email for further assistance regarding their legal rights.
